Compare PDC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDC | IMNN |
|---|---|---|
| Founded | 2018 | 1982 |
| Country | Japan | United States |
| Employees | 20 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 11.5M |
| IPO Year | N/A | 2000 |
| Metric | PDC | IMNN |
|---|---|---|
| Price | $7.00 | $2.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 111.6K | 37.7K |
| Earning Date | 07-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $0.37 |
| 52 Week High | $7.90 | $9.32 |
| Indicator | PDC | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 37.33 |
| Support Level | $3.99 | $2.52 |
| Resistance Level | N/A | $3.24 |
| Average True Range (ATR) | 0.86 | 0.17 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 81.15 | 16.00 |
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.